Search
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalPralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.
Piritramide
go.drugbank.com/drugs/DB12492ApprovedWithdrawnPiritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. … Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea and Vomiting.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLevamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigational[L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. … [L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers.[L10833] This medication was first marketed in Russia and India before being granted FDA approval.
Fecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalFor this type of therapy to be efficient, qualified donors must be selected. … [A259182,L46217,L46222] Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge.
Darifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalThis block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Products: ENABLEX ® 15 MG TABLETAS DE LIBERACION PROLONGADA, ENABLEX ® 7.5 MG TABLETAS DE LIBERACION PROLONGADAAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalto other preventative therapies. … It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsFencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnIt is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. … It is especially useful in patients with chronic conditions due to its favourable safety profile.
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigational[L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800] … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitorsVancomycin
go.drugbank.com/drugs/DB00512ApprovedInvestigationalIt is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. … As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis
Products: VANCOMICINA BONISCONTRO E GAZZONE, İNFÜZYONLUK VE ORAL ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ, 1 ADETMeningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
Mixtures: NIMENRIX 0,5 ML IM ENJEKSIYON ICIN TOZ ICEREN FLAKON VE COZUCU ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET